PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects

Basit Öğe Kaydı
dc.authorid0000-0002-8335-1927en_US
dc.contributor.authorPaydaş, Semra
dc.contributor.authorTanrıverdi, Kahraman
dc.contributor.authorYavuz, Sinan
dc.contributor.authorDisel, Umut
dc.contributor.authorBaşlamışlı, Fikri
dc.contributor.authorBurgut, Hüseyin Refik
dc.date.accessioned2024-07-12T21:01:27Z
dc.date.available2024-07-12T21:01:27Z
dc.date.issued2005en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractThe PRAME (preferentially expressed antigen of melanoma) gene has been shown to be expressed in high levels in some solid tumors and hemopoietic neoplasias but not or only weakly expressed in normal tissues. It encodes an antigen recognized by autologous cytolytic T lymphocytes. PRAME is a good candidate for tumor immunotherapy and is a useful marker gene for detection of minimal residual disease (MRD). In this study, PRAME mRNA using real-time RT-PCR was studied in 74 adult cases with acute leukemia-68 had de-novo acute leukemia, 3 had chronic myeloid leukemia-blastic crisis (CML-BC), and 3 had myelodysplastic/myeloproliferative syndrome-blastic transformation (MDS/MPD-BT)-and the results were compared with 30 age-matched healthy volunteers. Nineteen of 74 cases with leukemia expressed PRAME, while only 2 controls showed weak expression. The prevalence of PRAME expression in AML and ALL cases was 30% and 17%, respectively. We did not find any important correlation between PRAME expression and clinical characteristics, such as age, sex, organomegaly/lymphadenopathy, Hb, WBC count, platelet count, LDH level, alkaline phosphatase, albumin, cell-surface antigens, response to therapy, or progression-free and overall survival. PRAME was monitored in 15 cases during remission and/or relapse. There was a good correlation between PRAME mRNA and hematological remission and/or relapse. Interestingly, PRAME was very high in one case with AML but was not found 3 months after allogeneic transplantation. PRAME mRNA is observed in about one-third of AML cases; it may be a useful marker to detect MRD, and it may also be a good predictor for the timing of donor lymphocyte infusions (DLI) in the post-transplant period in cases of molecular relapse.en_US
dc.identifier.citationPaydaş, S., Tanrıverdi, K., Yavuz, S., Disel, S., Başlamışlı, F. ve Burgut, H. R. (2005). PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. American Journal of Hematology Journal. 79(4), s. 257-261.en_US
dc.identifier.endpage261en_US
dc.identifier.issue4en_US
dc.identifier.startpage257en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/16044453/
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3505
dc.identifier.volume79en_US
dc.institutionauthorBurgut, Hüseyin Refik
dc.language.isoenen_US
dc.publisherNational Center for Biotechnology Informationen_US
dc.relation.ispartofAmerican Journal of Hematology Journalen_US
dc.relation.isversionof10.1002/ajh.20425en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00170
dc.titlePRAME mRNA levels in cases with acute leukemia: clinical importance and future prospectsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu